CytomX
IPODestroy cancer, differently.
South San Francisco, United States · Founded 2008 · $120.0M raised
- Headquarters
- South San Francisco
- Employees
- 51–200
- Founded
- 2008
- Business Model
- B2B
- Total Funding
- $120.0M
- Last Round
- $70.0M Series DJun 2015
- Rounds
- 3
About
CytomX Therapeutics is a leading clinical-stage biopharmaceutical company in the growing field of conditional activation. The company was founded in 2008 based on technology licensed from the University of California at Santa Barbara (UCSB). CytomX develops Probody therapeutics, with a stated goal of reinventing biologic therapeutics to destroy cancer, differently.
Summary
CytomX is a Biotech company based in South San Francisco, United States, founded in 2008. It has raised $120.0M in total across 3 rounds, most recently a $70.0M Series D round in Jun 2015. Investors include Third Rock Ventures, Pfizer Ventures and Canaan Partners.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Oct 2015
Sign up to see all 4 rounds
Series B through IPO — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/cytomx"><img src="https://indexed.vc/api/badge/company/cytomx" alt="CytomX on Indexed.vc" width="260" height="76" /></a>